Press release
Zevra Announces Board of Directors and Leadership Changes
CELEBRATION, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"CELEBRATION, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced changes to the Company’s Board of Directors (“Board”) and leadership. At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board. Additionally, as previously announced, Wendy L. Dixon, Ph.D., joined the Zevra Board on the date of the Annual Meeting. After the Annual Meeting, Zevra’s newly configured Board met and unanimously approved the following changes: The Board accepted the resignation of Richard W. Pascoe from his role as CEO, effective June 1, 2023.Tamara A. Favorito was unanimously appointed Chair of the Board.Directors Matthew R. Plooster and Joseph B. Saluri, J.D. have indicated that they will not stand for re-election at the Company’s 2024 Annual Meeting, and that they intend to retire as soon as replacements are found. The Board intends to appoint an interim-Chief Executive Officer and will immediately initiate a search to identify both a new Chief Executive Officer and replacement Board members. “On behalf of the Zevra team, we welcome new directors John, Doug, Corey and Wendy to the Board as we strengthen our commitment to working together towards our shared goal of delivering value for all Zevra shareholders,” stated Tamara A. Favorito, Zevra’s Board Chair. “We also thank Dr. Travis Mickle, Richard Pascoe, Christopher Posner and Dr. David Tierney for their many contributions to the Company during their tenures on the Board and as leaders of the Company. I want to especially recognize their efforts and commitment to our shared vision of creating a commercially focused rare disease therapeutics company .” John B. Bode, Chair of the Nominating and Corporate Governance Committee, stated, “As we look ahead, we will prioritize a search for a Chief Executive Officer who will continue to execute upon the Company’s rare disease strategy and drive value creation for all shareholders. In the interim, I am confident in the existing management team’s ability to execute on the Company’s strategy.” About ZevraZevra Therapeutics is a rare disease company melding science, data, and patient need to create transformationa...